TP53 and B-cell chronic lymphocytic leukemia: In these studies, patients were being treated for relapsed or refractory CLL, which makes it difficult to ascertain how often cases of early transformation on novel treatment may be due to underlying undiagnosed RS prior to treatment initiation or presence of high-risk features, which prompted treatment with targeted agents (e.g., del(17p)/ TP53 inactivation).